Press Releases

Inspirata Partners with King’s Health Partners ECMC and Guy’s and St Thomas’ NHS Foundation Trust to Evaluate the Application of AI Automation in Matching Patients with Cancer to Early Phase Clinical Trials

Inspirata has announced that King’s Health Partners ECMC and Guy’s and St Thomas’ NHS Foundation Trust will pilot its Trial Navigator™ software as part of an evaluation the organisations are conducting into how artificial intelligence based automation can improve the identification and efficiency of matching patients with cancer to early phase clinical trials.

Cerba Research Awarded NIH Contract for Central Lab Services

Cerba Research today announced it was awarded a five-year contract for Clinical Central Laboratory Services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).

Biotium Launches First Ever Mounting Media with Far-Red Nuclear Counterstain and Autofluorescence Quenching Reagent

Biotium has announced that it is significantly expanding its line of antifade wet-set and hardset EverBrite™ Mounting Medium by launching a new far-red nuclear counterstain, NucSpot® 640 — specific for the Cy®5 channel.

Profacgen Provides Tandem Affinity Purification Service for Protein Interaction Research

Sensyne grows medical research dataset to 60 million patients

Deep longitudinal, disease agnostic structured global dataset, covering over 4,000 indications will industrialize Sensyne’s life sciences activities

Biofourmis Earns FDA’s First-Ever Breakthrough Device Designation for a Novel Digital Therapeutic for Heart Failure

Biofourmis completed a proof of concept study for its heart failure digital therapeutic BiovitalsHF that met its endpoint of number of patients at 50% of optimal therapy. As a result, FDA has granted the DTx the first-ever Breakthrough Designation for a heart failure digital therapy.

Glyscend Therapeutics Announces Preclinical Data at ADA 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

Glyscend Inc has presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, from a study of its proprietary oral polymer duodenal exclusion therapy.

Speranza Therapeutics Announces Value-Based Program for Opioid Detox Facilities Program vows to reduce costly facility Against Medical Advice (AMA) Leave rates

Speranza Therapeutics has announced the launch of a value-based program for treatment facilities to reduce patient Against Medical Advice (AMA) rates utilizing the S.T. Genesis device.

Curebase Names Paul Donnelly as Senior Vice President of Enterprise Strategy

Curebase Names Paul Donnelly as Senior Vice President of Enterprise Strategy

DFE Pharma demonstrates Impact of Powder Properties on the Rheological Behavior of Excipients

Heraeus completes multi-million Euro cancer therapy API capacity expansion

Heraeus Pharmaceutical Ingredients’ additional production line for Platinum-based highly potent active pharmaceutical ingredients (Pt hAPIs) is now fully operational at the company’s headquarters in Hanau, Germany.

NanoImaging Services Welcomes its First Chief Operating Officer as Company’s Expansion of Talent Continues

NanoImaging Services today announced the hire of its first Chief Operating Officer, Brian Conkle, as the company continues its rapid growth.

Veranex Announces Acquisition of Experien Group

Veranex, the first concept-to-commercialization global service provider dedicated to the medtech industry, today announced the acquisition of Experien Group, a leading provider of a full range of regulatory, quality, and clinical consulting services to medtech companies.

Panthera steps up its move into oncology trials with more than 12 trials in the pipeline and a prostate trial underway

Many cancer clinical research trials were put on hold during Covid – now Panthera Biopartners and Rutherford Health are working in partnership to accelerate oncology research in order to provide improved care for patients.

ADVANZ PHARMA partners with Ashfield Engage to deliver talent acquisition strategy for European specialty medicine division

Ashfield Engage, part of UDG Healthcare plc, announced that it has partnered with ADVANZ PHARMA to develop and deliver a pan-European talent acquisition programme for ADVANZ PHARMA’s specialty medicine division.

Sensyne Health and Sentara Healthcare Form New Partnership for Ethical Data Sharing and Design of New Clinical Algorithms

Combination of Viral Therapy and T Cell Therapy to Improve The Cure Rate of Cancer

IntegrateRNA Offers High-quality Oligonucleotide Conjuagted to Facilitate Diagnostic and Targeted Drug Delivery

Histobiolab: One-Stop Source for Blood Samples to Support Studying Progress of Disease Processes

Noxopharm Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) has reported pre-clinical data confirming a survival benefit of adding Veyonda® to 177lutetium-PSMA-617 (LuPSMA) treatment in prostate cancer.